 |
| Attached files |
| File | Filename |
|---|
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R15.htm |
| 10-Q - Q Therapeutics, Inc. | form10q.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R13.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R23.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R17.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R8.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc. | R25.htm |
| EX-32.2 - Q Therapeutics, Inc. | ex32-2.htm |
| EX-32.1 - Q Therapeutics, Inc. | ex32-1.htm |
| EX-31.2 - Q Therapeutics, Inc. | ex31-2.htm |
| EX-31.1 - Q Therapeutics, Inc. | ex31-1.htm |
| EX-14.1 - Q Therapeutics, Inc. | ex14-1.htm |
| EX-3.2 - Q Therapeutics, Inc. | ex3-2.htm |
| EX-3.1 - Q Therapeutics, Inc. | ex3-1.htm |
v2.4.0.6
|
Condensed Consolidated Statements of Cash Flows (Parenthetical)
|
126 Months Ended |
|
Sep. 30, 2012
|
| Statement of Cash Flows [Abstract] |
|
| Common shares issued in exchange for technology, shares |
219,658 |
| Conversion of notes payable and accrued interest into Series A2 Preferred stock shares |
482,008 |
| Conversion of notes payable and accrued interest into Series B Preferred stock shares |
1,787,104 |
| Non cash issuance of series B Preferred stock shares for research and development expenses, shares |
19,457 |
| Conversion of bridge notes payable and accrued interest into common stock, shares |
916,644 |
| Convertible Series A1 Preferred Stock |
250,000 |
| Convertible Series A2 Preferred Stock |
2,022,190 |
| Convertible Series B Preferred Stock |
4,102,654 |
| Converted 250,000 shares of Series A1 preferred stock, 2,022,190 shares of Series A2 preferred stock, and 4,102,654 shares of Series B preferred stock into 13,791,231 shares of common stock |
13,791,231 |
| Non cash common shares issued for licensing research and development assets |
10,000 |
| X |
- Definition
Non Cash Common SharesIssued For Licensing Research And Development Assets
+ References+ Details
| Name: |
qhoi_NonCashCommonSharesIssuedForLicensingResearchAndDevelopmentAssets |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Common SharesIssued In Exchange For Technology Shares
+ References+ Details
| Name: |
qhoi_NonCashCommonSharesIssuedInExchangeForTechnologyShares |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Conversion Of Bridge Notes Payable And Accrued Interest Into Common Stock Shares
+ References+ Details
| Name: |
qhoi_NonCashConversionOfBridgeNotesPayableAndAccruedInterestIntoCommonStockShares |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Conversion Of Notes Payable And Accrued Interest Into Series A 2 Preferred Stock Shares
+ References+ Details
| Name: |
qhoi_NonCashConversionOfNotesPayableAndAccruedInterestIntoSeriesA2PreferredStockShares |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Conversion Of Notes Payable And Accrued Interest Into Series B Preferred Stock Shares
+ References+ Details
| Name: |
qhoi_NonCashConversionOfNotesPayableAndAccruedInterestIntoSeriesBPreferredStockShares |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Convertible Series A 1 Preferred Stock
+ References+ Details
| Name: |
qhoi_NonCashConvertibleSeriesA1PreferredStock |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Convertible Series A 2 Preferred Stock
+ References+ Details
| Name: |
qhoi_NonCashConvertibleSeriesA2PreferredStock |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Convertible Series B Preferred Stock
+ References+ Details
| Name: |
qhoi_NonCashConvertibleSeriesBPreferredStock |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
Non Cash Issuance Of Series B Preferred Stock Shares For Research And Development Expenses
+ References+ Details
| Name: |
qhoi_NonCashIssuanceOfSeriesBPreferredStockSharesForResearchAndDevelopmentExpenses |
| Namespace Prefix: |
qhoi_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
+ Details
| Name: |
us-gaap_ConversionOfStockSharesIssued1 |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:sharesItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_StatementOfCashFlowsAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by Q Therapeutics, Inc. and has no official or unofficial affiliation with Q Therapeutics, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
